These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38717625)

  • 1. Estimation of linezolid exposure in patients with hepatic impairment using machine learning based on a population pharmacokinetic model.
    Liao R; Chen L; Cheng X; Li H; Wang T; Dong Y; Dong H
    Eur J Clin Pharmacol; 2024 Aug; 80(8):1241-1251. PubMed ID: 38717625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
    Crass RL; Cojutti PG; Pai MP; Pea F
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia.
    Takahashi S; Tsuji Y; Kasai H; Ogami C; Kawasuji H; Yamamoto Y; To H
    J Pharm Sci; 2021 May; 110(5):2295-2300. PubMed ID: 33609520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
    Wu X; Tang Y; Zhang X; Wu C; Kong L
    Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients.
    Dou L; Meng D; Dong Y; Chen L; Han X; Fan D; Dong H
    Int J Infect Dis; 2020 Jul; 96():105-111. PubMed ID: 32251797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.
    Jones SJ; Nichols KR; DeYoung HL; Cox EG; Knoderer CA
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):272-5. PubMed ID: 26407433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of population pharmacokinetics of linezolid in Chinese].
    Zhang L; Bai N; Liu YN; Wang R
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Dec; 39(12):924-928. PubMed ID: 27938541
    [No Abstract]   [Full Text] [Related]  

  • 10. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure.
    Liao R; Dong Y; Chen L; Wang T; Li H; Dong H
    Eur J Clin Pharmacol; 2023 Jan; 79(1):149-157. PubMed ID: 36434292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations.
    Codde C; Rivals F; Destere A; Fromage Y; Labriffe M; Marquet P; Benoist C; Ponthier L; Faucher J-F; Woillard J-B
    Antimicrob Agents Chemother; 2024 May; 68(5):e0141523. PubMed ID: 38501807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients.
    Cazavet J; Bounes FV; Ruiz S; Seguin T; Crognier L; Rouget A; Fourcade O; Minville V; Conil JM; Georges B
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):527-538. PubMed ID: 31853741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.
    Sasaki T; Takane H; Ogawa K; Isagawa S; Hirota T; Higuchi S; Horii T; Otsubo K; Ieiri I
    Antimicrob Agents Chemother; 2011 May; 55(5):1867-73. PubMed ID: 21357301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients.
    Wicha SG; Mair A; Chiriac U; Frey OR; Fuchs T; Gaasch M; Hagel S; Richter DC; Roberts JA; Röhr AC; Weigand MA; Brinkmann A
    Int J Antimicrob Agents; 2022 May; 59(5):106572. PubMed ID: 35307562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
    Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A
    Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.